Your browser doesn't support javascript.
loading
[Alzheimer's disease cerebro-spinal fluid biomarkers: A clinical research tool sometimes useful in daily clinical practice of memory clinics for the diagnosis of complex cases]. / Les biomarqueurs du liquide cérébro-spinal dans la maladie d'Alzheimer : un outil de recherche utile dans la pratique clinique courante des consultations mémoire pour les cas complexes.
Magnin, E; Dumurgier, J; Bouaziz-Amar, E; Bombois, S; Wallon, D; Gabelle, A; Lehmann, S; Blanc, F; Bousiges, O; Hannequin, D; Jung, B; Miguet-Alfonsi, C; Quillard, M; Pasquier, F; Peoc'h, K; Laplanche, J-L; Hugon, J; Paquet, C.
Affiliation
  • Magnin E; Centre mémoire de recherches et de ressource de Besançon, CHU de Besançon, 25030 Besançon, France. Electronic address: eloi.magnin@laposte.net.
  • Dumurgier J; Centre mémoire de recherches et de ressource Paris Nord Île-de-France, université Paris Diderot, Sorbonne Paris Cité, Inserm U942, groupe hospitalier Saint-Louis-Lariboisière-Fernand-Widal, AP-HP, 75205 Paris, France.
  • Bouaziz-Amar E; Service de biochimie et biologie moléculaire, université Paris-Descartes, Inserm UMRS-1144, groupe hospitalier Saint-Louis-Lariboisière-Fernand Widal, AP-HP, 75205 Paris, France.
  • Bombois S; Centre mémoire de recherches et de ressource, CHU de Lille, 59000 Lille, France.
  • Wallon D; Centre mémoire de recherches et de ressource, CHU de Rouen, 76000 Rouen, France.
  • Gabelle A; Centre mémoire de recherches et de ressource de Montpellier, CHU de Montpelier, 34000 Montpellier, France.
  • Lehmann S; Laboratoire de biochimie-protéomique clinique, IRMB, CCBHM, Inserm U11183, hôpital Saint-Éloi, université Montpellier, CHU de Montpellier, 34000 Montpellier cedex, France.
  • Blanc F; CMRR, service de gériatre, CHU, 67000 Strasbourg, France.
  • Bousiges O; Laboratoire de biochimie et de biologie moléculaire, CHU, 67000 Strasbourg, France.
  • Hannequin D; Centre mémoire de recherches et de ressource, CHU de Rouen, 76000 Rouen, France.
  • Jung B; CMRR, service de gériatre, CHU, 67000 Strasbourg, France.
  • Miguet-Alfonsi C; Laboratoire de pharmacologie clinique, CHU, 25000 Besançon, France.
  • Quillard M; Service de biochimie, hôpital universitaire de Rouen, 76000 Rouen, France.
  • Pasquier F; Centre mémoire de recherches et de ressource, CHU de Lille, 59000 Lille, France.
  • Peoc'h K; Service de biochimie clinique, hôpital Beaujon, AP-HP, 92110 Clichy, France.
  • Laplanche JL; Service de biochimie et biologie moléculaire, université Paris-Descartes, Inserm UMRS-1144, groupe hospitalier Saint-Louis-Lariboisière-Fernand Widal, AP-HP, 75205 Paris, France.
  • Hugon J; Centre mémoire de recherches et de ressource Paris Nord Île-de-France, université Paris Diderot, Sorbonne Paris Cité, Inserm U942, groupe hospitalier Saint-Louis-Lariboisière-Fernand-Widal, AP-HP, 75205 Paris, France.
  • Paquet C; Centre mémoire de recherches et de ressource Paris Nord Île-de-France, université Paris Diderot, Sorbonne Paris Cité, Inserm U942, groupe hospitalier Saint-Louis-Lariboisière-Fernand-Widal, AP-HP, 75205 Paris, France.
Rev Med Interne ; 38(4): 250-255, 2017 Apr.
Article in Fr | MEDLINE | ID: mdl-27890382
ABSTRACT
The role of biomarkers in clinical research was recently highlighted in the new criteria for the diagnosis of Alzheimer's disease. Cerebro-spinal fluid (CSF) biomarkers (total Tau protein, threonine 181 phosphorylated Tau protein and amyloid Aß1-42 peptide) are associated with cerebral neuropathological lesions observed in Alzheimer's disease (neuronal death, neurofibrillary tangle with abnormal Tau deposits and amyloid plaque). Aß1-40 amyloid peptide dosage helps to interpret Aß1-42 results. As suggested in the latest international criteria and the French HAS (Haute Autorité de santé) recommendations, using theses CSF biomarkers should not be systematic but sometimes could be performed to improve confidence about the diagnostic of Alzheimer's disease in young subjects or in complex clinical situations. Future biomarkers actually in development will additionally help in diagnostic process (differential diagnosis) and in prognostic evaluation of neurodegenerative diseases.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / Dementia / Alzheimer Disease Type of study: Diagnostic_studies / Guideline / Prognostic_studies Limits: Humans Language: Fr Journal: Rev Med Interne Year: 2017 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / Dementia / Alzheimer Disease Type of study: Diagnostic_studies / Guideline / Prognostic_studies Limits: Humans Language: Fr Journal: Rev Med Interne Year: 2017 Type: Article